Home > Insider Trading > Filing (0000899243-20-020725)

Filing Details

Accession Number:: 0000899243-20-020725
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-07-30 08:00:49
Reporting Period:: 2020-07-28

Accepted Time:: 2020-07-30 08:00:49
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1808865	Iteos Therapeutics Inc.	ITOS	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1134655	Ansbert Gadicke	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	Yes	No	Yes	No
1687078	Mpm Oncology Impact Management Lp	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	No	Yes
1691428	L.p. Fund Impact Oncology Ubs	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	No	Yes
1721035	Mpm Oncology Impact Management Gp Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	No	Yes
1721036	L.p. Management (Cayman) Fund Impact Oncology	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	No	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-07-28	1,269,230	$0.00	1,269,230	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	84,655	$0.00	84,655	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	43,687	$0.00	43,687	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	801,619	$0.00	801,619	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	42,605	$0.00	42,605	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	15,820	$0.00	15,820	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	1,397,574	$0.00	1,397,574	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	724,702	$0.00	1,993,932	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	48,336	$0.00	132,991	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	24,944	$0.00	68,381	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	457,706	$0.00	1,259,325	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	24,326	$0.00	66,931	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	9,033	$0.00	24,853	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	797,983	$0.00	2,195,557	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	89,955	$19.00	2,083,887	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	5,994	$19.00	138,985	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	3,096	$19.00	71,727	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	56,814	$19.00	1,316,139	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	3,020	$19.00	69,951	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	1,121	$19.00	25,974	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	160,000	$19.00	2,355,557	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2020-07-28	3,824,591	$0.00	1,269,230	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-07-28	255,094	$0.00	84,655	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-07-28	131,645	$0.00	43,687	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-07-28	2,415,530	$0.00	801,619	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-07-28	128,384	$0.00	42,605	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-07-28	47,674	$0.00	15,820	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-07-28	4,211,330	$0.00	1,397,574	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2020-07-28	2,361,805	$0.00	724,702	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2020-07-28	157,529	$0.00	48,336	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2020-07-28	81,295	$0.00	24,944	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2020-07-28	1,491,666	$0.00	457,706	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2020-07-28	79,281	$0.00	24,326	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2020-07-28	29,440	$0.00	9,033	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2020-07-28	2,600,628	$0.00	797,983	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date.
The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering.
(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering.
(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering.
(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP ("UBS Oncology") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020.
These securities are owned directly by MPM Bio Ventures 2014 LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein
These securities are owned directly by MPM Bio Ventures 2014 (B) LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein
These securities are owned directly by MPM Asset Management Investors BV 2014 LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein
These securities are owned directly by MPM Bio Ventures 2018 LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
These securities are owned directly by MPM Bio Ventures 2018 (B) LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
These securities are owned directly by MPM Asset Management Investors BV 2018 LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
These securities are owned directly by UBS Oncology. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing director of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date.
On July 28, 2020, MPM Bio Ventures 2014 LP purchased 89,955 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, MPM Bio Ventures 2014 (B) LP purchased 5,994 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, MPM Asset Management Investors BV 2014 LLC purchased 3,096 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, MPM Bio Ventures 2018 LP purchased 56,814 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, MPM Bio Ventures 2018 (B) LP purchased 3,020 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, MPM Asset Management Investors BV 2018 LLC purchased 1,121 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, UBS Oncology purchased 160,000 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.